US 9,809,539 B2
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
Scott Grindrod, Rockville, MD (US); Mira Jung, Rockville, MD (US); Milton Brown, Rockville, MD (US); and Anatoly Dritschilo, Rockville, MD (US)
Assigned to Shuttle Pharmaceuticals, LLC, Rockville, MD (US)
Filed by Shuttle Pharmaceuticals, LLC, Rockville, MD (US)
Filed on Mar. 3, 2015, as Appl. No. 14/636,736.
Prior Publication US 2016/0257649 A1, Sep. 8, 2016
Int. Cl. C07D 209/20 (2006.01); C07D 209/42 (2006.01); C07D 403/14 (2006.01); A61K 31/404 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61N 5/00 (2006.01); A61N 5/10 (2006.01)
CPC C07D 209/42 (2013.01) [A61K 31/404 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61N 5/00 (2013.01); C07D 209/20 (2013.01); C07D 403/14 (2013.01); A61N 2005/1098 (2013.01)] 6 Claims
 
1. A compound of the formula:

OG Complex Work Unit Drawing
for a pharmaceutically acceptable salt thereof.